APA (7th ed.) Citation

Perrot, A., Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., . . . Usmani, S. Z. (2021). Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. Blood, 138(Supplement 1), 1655. https://doi.org/10.1182/blood-2021-144421

Chicago Style (17th ed.) Citation

Perrot, Aurore, et al. "Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial." Blood 138, no. Supplement 1 (2021): 1655. https://doi.org/10.1182/blood-2021-144421.

MLA (9th ed.) Citation

Perrot, Aurore, et al. "Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial." Blood, vol. 138, no. Supplement 1, 2021, p. 1655, https://doi.org/10.1182/blood-2021-144421.